Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workers.

•Scientists handling Neisseria meningitidis are at increased risk for meningococcal disease.•Bivalent rLP2086 vaccination should protect against N. meningitidis serogroup B.•Vaccine immunogenicity, safety were tested in laboratory workers 24–62 years old.•Vaccination elicited protective immune responses against 4 diverse MnB strains.•These results support bivalent rLP2086 vaccination in this at-risk population.